Acute Encephalopathy in Critically Ill Patients With COVID-19
Märksõnad
Abstraktne
Kirjeldus
All patients with SARS-CoV-2 infection and acute encephalopathy at presentation will be prospectively included in the NEURO-COVD-19 study. This study will collect demographic data, clinical examen at prehospital/emergency room and ICU admission (including neurological signs), and all ancillary exams performed to identify a cause of neurological impairment. Outcome will be evaluated using the Glasgow Outcome Scale score at ICU and hospital discharge, and day-90 after ICU admission.
Acute encephalopathy will be defined as recently stated :
"1. The term acute encephalopathy refers to a rapidly developing (over less than 4 weeks, but usually within hours to a few days) pathobiological process in the brain. This is a preferred term 2. Acute encephalopathy can lead to a clinical presentation of subsyndromal delirium, delirium, or in case of a severely decreased level of consciousness, coma; all representing a change from baseline cognitive status 3. The term delirium refers to a clinical state characterized by a combination of features defined by diagnostic systems such as the DSM-5. Delirium according to the DSM-5 is defined if criterium A-E are fulfilled: A. Disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to the environment). B. The disturbance develops over a short period of time (usually hours to a few days) represents a change from baseline attention and awareness, and tends to fluctuate in severity during the course of the day. C. An additional disturbance in cognition (e.g., memory deficit, disorientation, language, visuospatial ability, or perception). D. The disturbances in criteria A and C are not explained by another pre-existing, established, or evolving neurocognitive disorder, and do not occur in the context of a severely reduced level of arousal, such as coma. E. There is evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiologic consequence of another medical condition, substance intoxication or withdrawal (i.e. because of a drug of abuse medication), or exposure to a toxin, or is because of multiple etiologies. " (Slooter, A.J.C., Otte, W.M., Devlin, J.W. et al. Updated nomenclature of delirium and acute encephalopathy: statement of ten Societies. Intensive Care Med (2020). https://doi.org/10.1007/s00134-019-05907-4)
Kuupäevad
Viimati kinnitatud: | 05/31/2020 |
Esmalt esitatud: | 03/21/2020 |
Hinnanguline registreerumine on esitatud: | 03/21/2020 |
Esmalt postitatud: | 03/24/2020 |
Viimane värskendus on esitatud: | 06/20/2020 |
Viimati värskendus postitatud: | 06/22/2020 |
Õppe tegelik alguskuupäev: | 03/22/2020 |
Eeldatav esmane lõpetamise kuupäev: | 11/30/2020 |
Eeldatav uuringu lõpetamise kuupäev: | 11/30/2020 |
Seisund või haigus
Sekkumine / ravi
Other: Follow up
Faas
Käerühmad
Arm | Sekkumine / ravi |
---|---|
Follow up Follow up of all included patients up to 3 months after enrollement | Other: Follow up Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale) |
Abikõlblikkuse kriteeriumid
Õppimiseks sobivad vanused | 18 Years To 18 Years |
Uuringuks kõlblikud sood | All |
Proovivõtumeetod | Non-Probability Sample |
Võtab vastu tervislikke vabatahtlikke | Ei |
Kriteeriumid | Inclusion Criteria: - Critical/Intensive care or Neurocritical care admission - Admission for/with acute encephalopathy defined as a rapidly developing (over less than 4 weeks, but usually within hours to a few days) pathobiological process in the brain; including delirium or subsyndromal (DSM V definition) or coma (Glasgow coma scale score < 9) - SARS-COV-2 infection (respiratory or other PCR specimen) - Age ≥ 18 years Exclusion Criteria: - Opposition to study participation from the patient itself or patient surrogate |
Tulemus
Esmased tulemusnäitajad
1. prevalence [at Critical/Intensive care or Neurocritical care admission]
Sekundaarsed tulemusmõõdud
1. Favorable outcome [3 months]
2. Favorable outcome [3 months]